There has been resurgent interest in Shigella as a human pathogen, driven by the availability of more precise data on the disease burden [5] [6] [7] [8] , emerging antibiotic resistance 9, 10 and the fact that mucosally invasive Shigella, which often cause dysentery (gross blood in diarrhoeal stools), are less amenable to the salutary effects of oral rehydration than non-invasive pathogens that cause watery diarrhoea, such as Vibrio cholerae and enterotoxigenic Escherichia coli. The target populations for the use of Shigella vaccines include infants and young children in developing countries (in whom the peak incidence occurs at 12-47 months of age and the S. flexneri serotypes predominate) [5] [6] [7] . S. dysenteriae 1, which produces Shiga toxin and typically carries R factors that encode resistance to multiple antibiotics, waxes and wanes as a cause of epidemic severe disease in the world's least developed countries [11] [12] [13] [14] .
Pandemics of Shiga dysentery, as occurred in Central
America from ~1968-1972 (REF. 11 ), South Asia in the 1970s 12 , Central Africa in the 1980s 13 and East Africa in the 1990s 14, 15 (FIG. 1) , profoundly influence the global mortality burden that can be attributed to Shigella 5, 15 . The lack of S. dysenteriae 1 endemicity results in low background immunity in populations, so epidemics of Shiga dysentery affect adults and children alike and the target ages for the use of a Shiga vaccine would be similarly broad 1, [11] [12] [13] . S. sonnei persists in developed (and transitional) countries, causing sporadic diarrhoea and occasional outbreaks in epidemiological niches (such as day-care centres) where personal hygiene can be suboptimal 16, 17 . Travellers from developed to developing regions, who mainly acquire S. sonnei and S. flexneri infections 18 , represent another target population for Shigella vaccines. Shigellosis due to S. boydii or S. dysenteriae serotypes other than type 1 is uncommon [5] [6] [7] (although increases in S. boydii have been reported in some foci 7 ). Consequently, a Shigella vaccine that can provide a high level of protection against S. dysenteriae 1, all S. flexneri serotypes and S. sonnei would constitute an epidemiologically valid 'global' vaccine Abstract | More than 50 years of research has yielded numerous Shigella vaccine candidates that have exemplified both the promise of vaccine-induced prevention of shigellosis and the impediments to developing a safe and effective vaccine for widespread use, a goal that has yet to be attained. This Review discusses the most advanced strategies for Shigella vaccine development, the immune responses that are elicited following disease or vaccination, the factors that have accelerated or impeded Shigella vaccine development and our ideas for the way forward.
strategies (BOX 2) , the relevance of the different immune responses measured, the factors that have favoured or impeded vaccine development and, most importantly, the lessons that must be learned for the future.
Shigellosis models and vaccine development
The ability of Shigella to cause diarrhoeal illness is restricted to human and higher non-human primate (NHP) hosts. Experimental models of shigellosis in adult human volunteers and NHPs have been invaluable for studying Shigella pathogenesis, infection and immunity as well as for evaluating candidate Shigella vaccines. Epidemiologically, shigellosis is a low-inoculum infection that is readily transmitted by direct faecal-oral contact. This has been corroborated by volunteer studies in which the ingestion of as few as ten S. dysenteriae 1 organisms induced a clinical infection rate of 10% 22 and 200 organisms of different serotypes caused infection rates that were >25% [22] [23] [24] [25] [26] . In a volunteer model of experimental shigellosis that was developed in the late 1960s, the Shigella inoculum was administered in skimmed milk without buffer 22, 23, 26, 27 . However, this was accompanied by considerable variability in the infection rate, particularly at lower inocula levels. A helpful modification was to administer the inoculum with NaHCO 3 buffer 25 , which achieved consistency in the rate of shigellosis 25, 28 (TABLE 2) . Volunteers develop classical bacillary dysentery, which commences with fever, malaise, abdominal cramps and (often watery) diarrhoea (for ~18-24 hours). These symptoms are followed by scanty stools that contain blood and mucus and by tenesmus 25 .
With early antibiotic therapy, volunteers rapidly respond clinically and microbiologically (their cultures are often negative within 24 hours) 25 . In contrast to the disease in humans, a large inoculum (~ 10 10 colony-forming units (CFU)) administered with NaHCO 3 is required to reliably induce shigellosis in NHPs [29] [30] [31] . So, although the NHP model is helpful for studying pathogenesis, infection-derived immunity and perhaps the efficacy of vaccines, it is not useful for predicting the clinical acceptability of putatively attenuated live vaccine candidates for humans.
The gross pathology of shigellosis in the human colon and the terminal ileum reflects the mucosal invasiveness of this pathogen. Understandably, most work on the molecular pathogenesis of Shigella infections has focused on the genes and gene products that are involved in invading epithelial cells and the host response to invasion 20, 21 . The early watery diarrhoeal phase of shigellosis was largely ignored until the NHP and volunteer model studies began to shed light on this stage of pathogenesis. Clinicians recognize that some patients with shigellosis manifest only watery diarrhoea, and even dysentery patients passing scanty bloody stools usually recount a day of watery diarrhoea without blood before the onset of their dysentery. When Rout et al. 32 fed virulent S. flexneri 2a to NHPs, some NHPs developed only watery diarrhoea, whereas others developed only dysentery and some manifested both. In vivo perfusion studies revealed that colonic net transport of water occurred in all clinically ill NHPs, whereas only NHPs with watery The first member of the genus Shigella to be identified, Shigella dysenteriae 1, was isolated by Kiyoshi Shiga during epidemics that occurred in Japan in the 1890s. Beginning in Central America in the late 1960s, pandemics of S. dysenteriae 1 caused severe disease with many complications and high case-fatality rates in all age groups. Subsequent pandemics occurred in Asia and Africa over the following 3 decades. diarrhoea exhibited net secretion of water, sodium and chloride ions in the jejunum, indicating the effect of an enterotoxin 32 . Histological examination demonstrated no jejunal abnormalities, corroborating the hypothesis that an enterotoxin (or toxins) was probably responsible for the watery diarrhoea. Kinsey et al. 33 proved that the initiation of watery diarrhoea required that S. flexneri 2a be present in the jejunum. When they bypassed the jejunum and inoculated NHPs directly in the cecum, the animals developed dysentery but not watery diarrhoea, and no jejunal secretion was observed 33 . The early watery diarrhoea phase, which can clearly be discerned in the volunteer model of shigellosis, prompted Fasano et al. to look for enterotoxins that could elicit small intestinal secretion in the absence of invasion [34] [35] [36] [37] . Their efforts led to the discovery and characterization of Shigella enterotoxin 1 (ShET1; encoded by the chromosomal gene set) and ShET2 (encoded by the plasmid-borne gene sen) [34] [35] [36] [37] . ShET1, a classical enterotoxin formed by a single A subunit that combines with five B subunits, is encoded on a chromosomal pathogenicity island 38 and is restricted to isolates of S. flexneri 2a [37] [38] [39] [40] [41] . By contrast, ShET2, which is encoded by a gene on an invasiveness plasmid, is expressed by all Shigella serotypes 36, [39] [40] [41] . The identification of these enterotoxins has had enormous repercussions for the development of well-tolerated live oral Shigella vaccine strains (TABLE 3) .
Immunity following wild-type infection
Convincing evidence that an initial clinical Shigella infection elicits serotype-homologous protection comes from three sources: NHP challenge studies 31 , volunteer model re-challenge studies 24, 25, 42 and prospective epidemiological surveillance of a cohort of children in an endemic area 6 . Formal et al. reported that an initial S. flexneri 2a diarrhoeal infection in NHPs conferred 100% protection against re-challenge with S. flexneri 2a, but offered no protection against challenge with S. sonnei 31 . For 30 months, Ferreccio et al. prospectively followed a cohort of children <4 years of age in a poor community in Santiago, Chile, where shigellosis was endemic. They found that 3 serotypes, S. sonnei, S. flexneri 2a and S. flexneri 6, caused 79% of the cases of shigellosis 6 . As these serotypes do not share O-antigen determinants
, this provided a unique opportunity to investigate the immunity that follows natural clinical exposure to each of these serotypes. By comparing the incidence of subsequent episodes of shigellosis caused by a homologous serotype against the overall incidence of subsequent episodes, it was calculated that an initial bout of shigellosis afforded 72% protection against a second clinical illness due to the homologous serotype (p=0.05) 6 . Protection against a second clinical illness due to a heterologous serotype was low (<30%; p>0.25). Collectively, these data suggest that antibodies to Shigella O-antigen have a key role in protection (FIG. 3) .
The debate over whether protection is predominantly mediated by mucosal secretory IgA (sIgA) anti-O-antigen antibodies, by serum IgG antibodies or by both (perhaps with contributions from other immune effector mechanisms) is more contentious. Strong mucosal (faecal and urinary) sIgA anti-O-antigen antibody responses are observed following wild-type infection 25, 28, [43] [44] [45] [46] [47] and experimental challenge 25, 28 . Moreover, priming of the mucosal immune system following an initial wild-type Shigella infection has also been documented by enumerating gut-derived IgA anti-O-antigen antibody-secreting cells (ASCs) 25, 28, 46, 48 (FIG. 3) . On the one hand, although IgA anti-O-antigen ASCs and serum anti-O-antigen IgG have generally been considered key elements for protection, some studies have failed to show an association between these responses and resistance to illness following challenge 49, 50 . In volunteer re-challenge studies, the substantial clinical protection exhibited by veterans 24, 25, 42 is accompanied by an ~1 log reduction in the level of excretion of Shigella 25 . In one endemic situation, initial clinical infection by S. flexneri 2a was followed by repetitive asymptomatic infections by that serotype and ultimately by sterile intestinal immunity such that even asymptomatic carriage was no longer detected 51 . On the other hand, the importance of mucosal antibodies in preventing shigellosis was demonstrated by Tacket et al. who reported that passive oral administration of cow's milk immunoglobulin that contained high titres of anti-S. flexneri 2a antibodies protected volunteers from experimental challenge with wild-type S. flexneri 2a strain 2457T 52 . Notably, cow's milk immunoglobulin that contained low titres of anti-S. flexneri 2a antibodies did not provide protection 52 . Additional research is needed to define the roles of intestinal sIgA and serum IgG antibodies in mediating protection against Shigella. The lipopolysaccharide (LPS) of Shigella, a virulence factor 119, 120 , consists of a toxic lipid A moiety embedded in the bacterial outer membrane, a core sugar region and an exposed terminal O polysaccharide. Whereas there is little diversity in lipid A and core regions among Shigella, the terminal O polysaccharide structures vary greatly, thereby giving rise to the immunological specificity that results in distinct serotypes (and subserotypes) 4 . Serotyping of Shigella flexneri is complicated. Current taxonomy recognizes 14 classical S. flexneri serotypes or subserotypes 4 , defined by type (I, II, IV-VI) and group (3, 4; 6;7, 8) antigens (see left panel of the figure) . Notably, the group antigens are shared among different serotypes. Type III antigen is not shown in the figure, as no structure can be assigned to it 121 . Moreover, absorbed rabbit 'type III' antisera actually bind group 6 antigen, indicating that type III antigen is identical to group 6 antigen, which is present in other serotypes 121 . Nevertheless, re-classification is unnecessary as strains heretofore characterized as S. flexneri 3a and 3b can be readily identified with absorbed or monoclonal typing sera 4, 121, 122 ; S. flexneri 3a agglutinate with antisera to group 6 and 7,8 antigens and S. flexneri 3b agglutinate with antisera to group 6 and 3,4 antigens (left panel) 121 . Thirteen of the 14 classical S. flexneri serotypes or subserotypes (all except S. flexneri 6) share a common backbone of tetrasaccharide repeats that contain three rhamnose residues and one N-acetylglucosamine (right panel). Genes that encode proteins involved in the synthesis of the linear backbone are located in the rfb locus of the chromosome, whereas lysogenic phages encode the enzymes that link O-acetyl groups or d-glucose at various sites on the tetrasaccharide backbone, thereby creating or ablating antigenic epitopes. The resultant O-antigens, the structures of which are displayed schematically in the right panel of the figure, provide the basis for the distinct S. flexneri serotypes or subserotypes. S. flexneri 6 has d-galactose as the third sugar of the tetrasaccharide and N-acetylgalactosamine as the terminal residue (right panel). The structure of S. flexneri 4c is not shown as it has not been reported.
As Shigella dysenteriae 1 and Shigella sonnei are two serotypes that should be included in a global Shigella vaccine, the basic structures of their O polysaccharide repeats are also shown 103, 123 . In contrast to the other O-antigens that have tetrasaccharide repeats, the O-antigen repeat of S. sonnei is a disaccharide (FucNAc, 2-acetamido-4-amino-2,4,6-trideoxy-d-galactose; AltUA, 2-amino-2-deoxy-l-altruronic acid) 103 . The S. dysenteriae 1 O polysaccharide repeat most closely resembles the structures of S. flexneri 6 and S. flexneri Y of the S. flexneri subtypes.
The left panel displays the 14 S. flexneri serotypes and subserotypes along the horizontal axis and the type and group antigens in the vertical axis. Below each serotype or subserotype, the specific type and group antigens expressed are indicated by a plus sign. As the O-antigens (circled) of S. flexneri 2a and S. flexneri 3a crossreact with 10 other S. flexneri serotypes or subserotypes, S. flexneri 2a, S. flexneri 3a and S. flexneri 6 have been proposed as three components of a pentavalent vaccine (along with S. dysenteriae 1 and S. sonnei) that could confer broad protection. Cross-protection among S. flexneri subserotypes has been demonstrated in a guinea pig model 118 . A high priority is to test this strategy in humans.
T helper 1
(T H 1 cell). A type of activated T H cell that promotes responses associated with the production of a particular set of cytokines, including interleukin-2 and interferon-γ, the main function of which is to stimulate phagocytosis-mediated defences against intracellular pathogens.
Other immune effector mechanisms have also been described in shigellosis (FIG. 3) . Increases in serum antiIpa (invasion plasmid antigen) antibodies have been demonstrated after natural disease and experimental challenge 25, 43, 53 , and in endemic areas the seroprevalence of anti-Ipa antibodies increases with age 43, 54 . A few studies have also measured cell-mediated immunity (CMI) elicited by wild-type Shigella infection. Rectal biopsies from Bangladeshis during acute and convalescent S. flexneri and S. dysenteriae 1 infection revealed an increased frequency of cytokine-producing cells and mononuclear cell infiltration in the rectal mucosa 55 . Increased levels of interferon-γ (IFN-γ) in plasma and stool, upregulation of IFN-γ receptor expression in patients with shigellosis and increased IFN-γ production during convalescence suggest that this cytokine might play a role in both pathogenesis and protection [55] [56] [57] [58] [59] . Upon stimulation with Shigella antigens (including Ipa), the production of IFN-γ and interleukin-10 (IL-10), but not IL-4, IL-5, IL-12 or IL-15, was demonstrated in peripheral blood mononuclear cells (PBMC) from volunteers challenged with modified virulent S. dysenteriae 1 strain SC595, indicating a predominant T helper 1 (T H 1)-type response 60 . Also, increased proportions of memory T cells (CD45RO + ), the expression of T-cell activation molecules (for example, CD25, CD38, HLA-DR and CD54) and the expansion of defined T-cell receptor Vβ families have been reported in patients with shigellosis 61, 62 . Despite these findings, the contribution to protection from Shigella that can be attributed to CMI or to antibodies directed at Shigella proteins (such as Ipa and VirG) rather than O polysaccharide antigens remains controversial (FIG. 3) . 
Phase III trial
Refers to a large-scale field trial of rigorous epidemiological design to determine the efficacy of a vaccine. When feasible, the preferred design involves a randomized, controlled, adequately powered, double-blind study in which allocation of vaccine or control regimen takes place at the level of the individual subject. Phase III trials, which are usually designated as pivotal studies for licensure, use a final formulation of the vaccine.
Protective prototype vaccines Two prototype Shigella vaccines, one which uses attenuated strains as live oral vaccines and the other which uses parenteral conjugates of Shigella O polysaccharide covalently linked to a carrier protein, have conferred significant protection in controlled Phase III trials. As these vaccines are furthest along in development, and as the results of the multiple clinical trials that have been carried out collectively provide insights, they will be discussed in depth. Other publications address promising alternative strategies (BOX 2) to develop Shigella vaccines 63 .
In the 1960s, Mel of the Military Medical Institute, Belgrade, Yugoslavia (Serbia), serially passaged different Shigella serotypes on streptomycin-containing media until they became streptomycin-resistant and streptomycin-dependent (SmD; that is, they could not grow in the absence of exogenous streptomycin) 64, 65 . These SmD strains lost their ability to cause purulent keratoconjunctivitis in guinea pigs, a reliable test for Shigella mucosal invasiveness, intercellular spread and propensity to cause inflammation 66 . At the time, the genetic changes responsible for the attenuation were unknown. In addition to testing the vaccines in adults and children in Yugoslavia [67] [68] [69] [70] , SmD Shigella vaccines were tested in adults and children in institutions in the United States where the risk of aquiring shigellosis was high 42 ,51,71-73 .
These vaccine strains proved to be well tolerated clinically when administered to adults, healthy children and even debilitated institutionalized children 42, 51, [71] [72] [73] , with the main adverse reaction being vomiting in a small percentage of recipients following administration of the first dose 51, [69] [70] [71] [72] [73] [74] . The vaccines were typically administered in an escalating (2×10 10 , 3×10 10 , 4×10 10 and 5×10 10 CFU) 4-dose regimen over 11 days. In controlled field trials, Mel et al. demonstrated the efficacy of the SmD vaccines 69, 70 , showed that multiple strains could be mixed together in combination vaccines and reported that protection was serotype-specific [68] [69] [70] . Protection endured for 1 year following primary immunization of children; however, administration of a single booster extended protection for an additional year 70 . These pioneering studies, which involved ~36,000 adult and paediatric subjects, provided proof of concept for future modern multivalent vaccines that aim to confer broad-spectrum protection. Unfortunately, the SmD vaccine strains had drawbacks that precluded them from becoming licensed for widespread use. In addition to the fact that the basis for the attenuation was unknown, occasional lots reverted to streptomycin independence (although the organisms remained unable to invade epithelium) and difficulties were encountered in large-scale manufacture and process control 73, 75 . . In all countries, S. flexneri 2a (marked with an asterisk) is the single most important S. flexneri subserotype. The most developed of the countries, Chile and Thailand, show a notable proportion of cases due to Shigella sonnei. In any individual country, 3-4 serotypes constitute ~75% of all cases. However, the other important S. flexneri serotypes, in addition to S. flexneri 2a, differ from country to country. Serotype 1c described in some studies is a provisional serotype. If the Center for Vaccine Development (CVD) pentavalent vaccine strategy that incorporates S. flexneri 2a, S. flexneri 3a and S. flexneri 6 (along with Shigella dysenteriae 1 and S. sonnei) succeeds in conferring cross-protection against the other 11 classical S. flexneri serotypes in future field trials, it should be possible to achieve a broad-spectrum global vaccine against shigellosis. S. dysenteriae type 1 were identified only in Kenya, where they comprised 67% of S. dysenteriae isolates. NT, non-typable.
Phase I trial
Initial evaluation of the safety and immunogenicity of a vaccine in small groups of healthy subjects who, in a stepwise manner, receive increasing dosage levels of the vaccine. For live vaccines, vaccine shedding is also monitored. If the Phase I study is conducted under physical containment (such as in a research isolation ward), one can preliminarily assess the propensity of the live vaccine to be transmitted by including several placebo recipients as contact controls.
Phase II trial
Expanded (usually placebo controlled) studies of the safety, clinical acceptability and immunogenicity of a vaccine in larger numbers (often tens or hundreds) of subjects who exemplify the target age and other characteristics for the use of the vaccine. Phase II trials aim to identify the optimal dosage level, formulation and immunization regimen of the vaccine to be used in the target groups, thereby paving the way for a pivotal Phase III efficacy trial.
S. flexneri 2a strain T 32 is another pioneering vaccine strain developed by Istrati in Romania, where it was shown to be well tolerated and probably protective 76, 77 . Subsequently, in randomized placebo-controlled field trials in China, Bingrui et al. reported that T 32 conferred significant protection against S. flexneri 2a diarrhoea 78 . Surprisingly, the Chinese field trials also suggested that T 32 conferred significant (albeit lower level) protection against shigellosis due to S. flexneri 1b and S. boydii 1-6. Investigators at the Walter Reed Army Institute of Research (WRAIR) revealed that T 32 harboured a large deletion in the invasiveness plasmid. This deletion resulted in the loss of three loci, ipaBCDA, invA and virG (also known as icsA), which crippled the ability of this strain to invade epithelial cells 79 . Further investigation showed that the T 32 plasmid deletion encompassed sen (which encodes ShET2); the chromosomal set gene (which encodes ShET1) remained intact 39 . In S. sonnei, the rfb locus, which encodes O-antigen, is located on the form I invasiveness plasmid. Formal et al. at WRAIR prepared a 'mutant-hybrid' S. flexneri 2a vaccine strain by selecting a colonial mutant that had lost its ability to invade intestinal epithelial cells 81 and transferred into it the xyloserhamnose region of E. coli (which diminishes the ability of Shigella to propagate in the lamina propria even if epithelial invasion occurs) 82 . The importance of the parent strain One lesson that has been learned in developing attenuated Shigella vaccines is the importance of starting with a wild-type parent strain of known virulence, ideally as assessed in volunteer studies. The paradigm is the array of derivatives of wild-type S. flexneri 2a strain 2457T, a parent strain known to be virulent in North American volunteers and to cause diarrhoea, fever and dysentery with an infection rate that increases with escalating doses 25, 49, 50 (TABLE 2) . Moreover, an initial clinical episode of 2457T-induced shigellosis stimulates immunity that confers ~64-75% protection against illness upon subsequent re-challenge with this strain 25, 42 . As the baseline virulence of the parent strain is well documented, the degree of attenuation achieved by putative attenuating mutations can be quantified
It is difficult, however, to draw conclusions about the ability of specific mutations to cause attenuation when they are introduced into wild-type parent strains that were either not tested clinically beforehand or, if tested, were found to be only minimally pathogenic in humans. Two illustrative examples are wild-type S. flexneri Y strain SF1 and a Shiga-toxin-deleted derivative of wild-type S. dysenteriae 1 strain SC595 (which retains
Box 2 | Shigella vaccine strategies
Strategies for which there is evidence from field trials that demonstrates efficacy:
• Attenuated strains of Shigella used as live oral vaccines.
• O polysaccharides of Shigella covalently linked to carrier proteins and used as parenteral conjugate vaccines.
Strategies that are being (or have been) pursued but for which evidence of protection in humans has not been documented:
• Proteosomes (outer membrane vesicles of group B Neisseria meningitidis) to which Shigella sonnei or Shigella flexneri 2a is adsorbed 124 . This vaccine has been administered to humans intranasally.
• Inactivated S. sonnei administered orally 125 .
• Shigella invasion complex (Invaplex); a subcellular vaccine prepared from pathogenic S. flexneri, containing proteins including invasion plasmid antigen B (IpaB) and IpaC and lipopolysaccharide, administered to humans intranasally 126 .
• Nuclear protein-ribosomal parenteral vaccine prepared from a Shigella strain that has been genetically attenuated by an msbB mutation that partially detoxifies the lipid A portion of the Shigella endotoxin 127, 128 . 
Community volunteers
Community volunteers is a term commonly used to refer to volunteers in a defined population that participate in clinical trials.
epithelial cell invasiveness and causes keratoconjunctivitis in guinea pigs). In the case of the S. flexneri Y strain SF1, an aroD mutation was introduced, resulting in attenuated putative vaccine candidate SFL124 (REF. 83 ). Subsequently, however, when the wild-type S. flexneri Y parent strain SF1 was fed to North American volunteers, it was only minimally pathogenic 84 . So, it was not possible to attribute the clinical behaviour of the vaccine strain to the introduced mutation. By contrast, when an aroD deletion was introduced into the well-characterized wild-type S. flexneri 2a strain 2457T, resulting in vaccine strain SFL1070, it was clearly demonstrated that this mutation afforded measurable attenuation 85 . Similarly, S. dysenteriae 1 strain SC595 caused only low rates of mild diarrhoeal illness when administered to North American volunteers (except in one subject who developed dysentery) 60 . SC595 did, however, elicit robust antibody and CMI responses following ingestion of as few as 300 CFU 60 . Not surprisingly, SC599, a derivative of SC595 that contains deletions in icsA (also known as virG; this deletion diminishes the intracellular and intercellular spread of Shigella), ent and fep (which encode proteins involved in iron chelation) was well tolerated in Phase I safety trials 63 . However, SC599 was only minimally excreted and induced only modest anti-O-antigen ASC responses and few anti-O-antigen seroconversions 63 .
Selection of attenuating mutations
The phenotypic consequences of introducing different mutations into wild-type S. flexneri 2a strains have been evaluated in Phase I clinical trials. These mutations include aroD and aroA (which encode enzymes in the aromatic amino-acid biosynthesis pathway; mutation confers auxotrophy for substrates not found in sufficient concentration in mammalian tissues) 85, 86 , virG 28, 87 , iuc (which encodes aerobactin) 28 , guaBA (which encodes enzymes involved in guanine-nucleotide biosynthesis) 87, 88 , set (which encodes ShET1) and sen (which encodes ShET2) 87, 88 . The experience with strain SC602, a derivative of wild-type strain Pasteur Institute S. flexneri 2a 494 with mutations in virG and iuc, is instructive 28, 89 . When fed to North American volunteers, dosages >10 6 CFU were unacceptably reactogenic, with most subjects developing diarrhoea, fever or severe constitutional symptoms, although the vaccine strain was heavily shed and highly immunogenic 28 . By contrast, at a dosage level of 10 4 CFU, adverse clinical reactions were uncommon and mild, yet the induced immune response remained moderately robust 28 . Eight weeks after vaccinees received a single 10 4 CFU dose of SC602, 7 vaccinees (and 7 unvaccinated control volunteers) participated in an experimental challenge study and ingested 10 3 CFU of virulent S. flexneri 2a strain 2457T 28 . Diarrhoea was observed in 86% of the controls and in 43% of the vaccinees (p=0.27) 28 . However, the 3 vaccinees that developed diarrhoea had significantly milder illness than the controls. Four of the 7 controls (57%) developed dysentery, 6 (86%) had fevers (mean temperature 39 o C) and 6 (86%) manifested severe shigellosis. By contrast, none of the vaccinees had dysentery, fever or severe illness (p=0.0027) 28 . This hallmark study showed that in the experimental challenge model even a single dose of an engineered vaccine strain could confer significant protection against severe shigellosis. However, it also demonstrated the difficulty of finding a proper balance between clinical acceptability and immunogenicity in adult volunteers in developed countries. Indeed, additional studies with SC602 in 34 community volunteers showed that 10 4 CFU caused mild diarrhoea in 5 volunteers (15%) and fever in 4 volunteers (12%) 89 . Invaluable lessons have also been learnt from clinical trials with the series of attenuated derivatives of wild-type S. flexneri 2a strain 2457T that was developed by the University of Maryland Center for Vaccine Development (CVD), as the results have directed iterations in vaccine design. CVD 1203 is a derivative of 2457T that harbours deletions in aroA and virG 90 . In a Phase I clinical trial in 10 North American adults, CVD 1203 was well tolerated at a dose of 10 6 CFU (a dosage level at which SC602 was extremely reactogenic) 86 . However, when administered at doses of 10 8 CFU or 10 9 CFU 86 , CVD 1203 induced unacceptable reactogenicity accompanied by strong immune responses 86 . Significant increases in the concentrations of tumour-necrosis factor-α (TNF-α) were observed in serum and stool, suggesting that this cytokine might be related to the reactogenicity observed at high doses 86 . Although the potent immune responses to CVD 1203 were encouraging, the reactogenicity dictated that alternative mutations should be evaluated to achieve a satisfactory degree of attenuation. , and even at 10 9 and 10 10 CFU only a few volunteers experienced mild diarrhoea 87 . The conclusion from the Phase I clinical trial of CVD 1207 was that the mutations definitively attenuated the 2457T parent strain, resulting in a vaccine that was well tolerated by North American volunteers at high dosage levels yet remained immunogenic. However, it was hypothesized that strain CVD 1207 could have been hyperattenuated 87 . CVD 1204 and CVD 1208, isogenic derivatives of wild-type strain 2457T, both carry deletions in guaBA 88, 91 , and CVD 1208 also has deletions in sen and set. These strains differ from isogenic CVD 1207 by having an intact virG gene. This design permitted researchers to assess the impact of inactivating ShET1 and ShET2 (TABLE 3) . A randomized, doubleblind clinical trial was performed in adult North Americans who ingested a single dose containing 10 7 , 10 8 or 10 9 CFU of either strain 88 . Objective adverse reactions were observed in 35% of CVD 1204 recipients but only in 4% of CVD 1208 recipients (p=0.02) 88 . Immune responses to S. flexneri 2a O-antigen (ASCs, serum IgG or faecal IgA) were observed in 86%, 43% and 100% of CVD 1208 recipients, respectively. The enterotoxin-negative strain CVD 1208 was considered a highly attractive vaccine candidate that reflects the desired balance of clinical acceptability and robust immunogenicity (TABLE 3) . As this strain was constructed using culture media that contained animal products, it was reconstructed using soy-based media for regulatory purposes, resulting in strain CVD 1208S. In a Phase I clinical trial, CVD 1208S demonstrated the same clinical acceptability, shedding pattern and immunogenicity as CVD 1208 (K.L.K., unpublished data). Thus, CVD 1208S, like CVD 1208, exhibits the desirable balance of low reactogenicity and robust immunogenicity.
Investigators at WRAIR constructed strain WRSS1 by deleting virG in the wild-type S. sonnei Moseley strain 92 . Although the virulence of this S. sonnei strain had not been demonstrated in volunteers, it was selected because its form I invasiveness plasmid (required for expression of O-antigen by this serotype) was remarkably stable, in contrast with the form I plasmid of most wild-type S. sonnei strains 24, 93 . In a Phase I trial in North American volunteers given a single dose of up to 10 6 CFU, low-grade fever or mild diarrhoea was recorded in 6 of 27 (22%) WRSS1 vaccinees 94 . Strong IgA anti-O-antigen ASC responses were observed in recipients of all dosage levels 94 . Moderate IFN-γ responses were also observed in some volunteers 94 . Safety and immunogenicity trials of WRSS1 were next performed in Israel in community adults who ingested 10 3 , 10 4 or 10 5 CFU 95 . At the two lower dosage levels, the vaccine was well tolerated with the exception of 1 of 30 subjects (3%) who developed moderate diarrhoea, and 5 (17%) who experienced mild diarrhoea. By contrast, at the 10 5 CFU dosage level, 2 of 15 subjects (13%) developed fever and 4 (27%) experienced moderate diarrhoea 95 . The So, certain attenuating mutations introduced into wild-type strains in recent years have generated promising vaccine candidates. Some modifications, for example deletion of the genes that encode ShET1 and ShET2, might work well in combination with an array of other attenuating mutations. If commercial and intellectual property considerations do not create barriers, it would be of interest to 'mix and match' novel combinations of attenuating mutations that have not previously been used in the same strains. For example, in their latest generation of live vaccine candidates, WRAIR investigators have deleted the ShET-encoding genes in strains that carry a virG deletion as the primary attenuating mutation (M. Venketasan, personal communication). Similarly, it would be instructive to directly compare the clinical acceptability and immunogenicity of two or more candidate live vaccine strains of the same serotype in randomized, double-blind clinical trials. Last, it has generally been proposed that once attenuating mutations have been documented in one serotype, they can be introduced into other epidemiologically relevant serotypes. However, if the commercial considerations can be managed, another track towards licensure of a broadly protective vaccine would be to combine promising strains of several different serotypes that have been attenuated by distinct mutations.
Hybrid live vector Shigella vaccines
As an alternative strategy to construct live Shigella vaccines, several research groups have attempted to express Shigella O-and other (Ipa) antigens in welltolerated live vectors such as normal flora, rough E. coli or highly attenuated Salmonella enterica serovar Typhi. The genes that allow synthesis of group-and type-specific O-antigens of S. flexneri 2a were introduced into an E. coli O8 strain, resulting in the vaccine strain PGAI 42-1-15. This hybrid E. coli expressing S. flexneri 2a O-antigen was well tolerated when given to adult US volunteers and was excreted for several days 27 . In two separate large experimental challenge studies, volunteers given two (first study) or three (second study) doses of vaccine one month apart were challenged 4-8 weeks later with 10 4 CFU (first study) or 10 2 CFU (second study) of virulent S. flexneri 2a strain 2457T 27 . The rates of shigellosis were similar in vaccinees and controls 27 . It was unclear why this live vaccine failed to protect. However, one hypothesis is that to be protective, an E. coli live vector strain expressing Shigella O-antigens must also exhibit the capacity to invade epithelial cells 27 . Accordingly, investigators at WRAIR constructed two E. coli live vector strains expressing S. flexneri 2a O-antigen that manifested epithelial cell invasiveness.
The invasiveness plasmid of S. flexneri 5 and the genes that allow expression of S. flexneri 2a type and group-specific O-antigens were introduced into E. coli K12, producing a strain, EcSf2a-1, that could invade epithelial cells 49 . At a dose of 10 9 CFU, this strain was unacceptably reactogenic as 4 of 13 (31%) vaccinees developed fever, diarrhoea or dysentery.
However, at lower, better-tolerated dosage levels, the vaccine failed to protect vaccinees against experimental challenge with S. flexneri 2a 49 . In an attempt to diminish reactogenicity, an aroD deletion was introduced, resulting in the further derivative strain EcSf2a-2 (REF. 96 ). At high dosage levels, this strain, which retained the ability to invade epithelial cells, also caused adverse reactions but was strongly immunogenic. However, despite robust immunogenicity, the vaccine conferred only 36% protection against illness (fever, diarrhoea or dysentery) upon experimental challenge (p=0.17) 50 . Overall, E. coli, with or without epithelial invasiveness, has been unsuccessful as a live vector vaccine expressing Shigella O-antigen.
In the 1980s, Formal and co-workers at WRAIR developed a vaccine candidate that consisted of licensed oral Salmonella Typhi live vaccine strain Ty21a engineered to express the O polysaccharide of S. sonnei 97 . This live vector strain, 5076-1C, was well tolerated but exhibited lot-to-lot variability in its immunogenicity and ability to protect in challenge studies in which vaccinees and controls ingested wild-type S. sonnei strain 53G 24, 48, 98 ; however, two pilot lots did confer significant protection 93 . Multiple hypotheses were pursued to explain the lot-to-lot variability in efficacy [99] [100] [101] [102] , but none were predictive and further development of 5076-1C was abandoned 24 . To overcome the inconsistency of 5076-1C, Kopecko and co-workers attempted to more reliably express S. sonnei O-antigen in Ty21a, as well as O-antigens from other serotypes 103 . As Salmonella has a lipopolysaccharide (LPS) core that is chemically distinct from that of Shigella
103
, S. sonnei O polysaccharide in Salmonella Typhi is expressed only as a non-core-linked surface-associated antigen 103 . Clinical trials are required to assess if these new Ty21a-based constructs will offer more consistent protection.
Intestinal barrier in developing countries
Oral vaccines against polio, rotavirus and cholera have exhibited lower immunogenicity in underprivileged subjects in developing countries compared with subjects in developed countries [104] [105] [106] [107] . The immunogenicity of some of these vaccines was successfully enhanced by increasing the number of vaccine organisms per dose or by administering additional doses of vaccine 104, 106 . Although S. flexneri 2a vaccine strain SC602 had been reactogenic in North American adults, as it conferred protection against severe disease in an experimental challenge, Phase I and II trials were undertaken in adults and children in a developing country. None of 68 Bangladeshi adults who ingested up to 10 6 CFU of SC602 experienced adverse reactions, but neither did any vaccinee shed SC602, and the immune responses induced were meager 63 . Next, Bangladeshi children of 8-10 years of age and 12-36 months of age ingested up to 10 6 CFU
63
. Although no child manifested an adverse reaction, neither did any child excrete the vaccine strain or mount a significant immune response. So, the developing country subjects manifested markedly different clinical, bacteriological and immunological responses to SC602 compared with North American subjects. In adults in the United States, a low dose (10 4 CFU) of SC602 was reactogenic, heavily excreted and moderately immunogenic, whereas in the children and adults in Bangladesh it was virtually inert, even in a 100-fold higher dose 63 . One possible hypothesis to explain these divergent results is that Bangladeshis have decreased levels of accessible iron in tissues compared with subjects in developed countries, so that SC602 is more crippled in individuals in developing countries.
Does this mean that most live oral Shigella vaccines will be poorly immunogenic in developing country populations? The response of Vietnamese adults 83 and children 108 to the ingestion of S. flexneri Y strain SFL124 (an aroD-deletion mutant) and the efficacy of the SmD and T32 live oral Shigella vaccines in subjects in Yugoslavia (late 1960s and early 1970s) 69, 70 and China (1980s) 78 , respectively, suggest not. A single 2×10 9 CFU dose of SFL124 was administered to 15 Vietnamese adult volunteers, whereas another 15 subjects ingested three doses (at an interval of two days between doses) 83 . No subjects manifested fever or diarrhoea, SFL124 was excreted by all volunteers and was immunogenic. Although few subjects excreted the strain, SFL124 was also immunogenic in Vietnamese children of 9-14 years of age and stimulated local mucosal immune responses and ASC responses to S. flexneri Y O-and Ipa antigens in a dose-dependent manner 108 . The high baseline titres of serum antibodies to S. flexneri Y O-and Ipa antigens in the Vietnamese children indicate that the vaccine was seen as a booster rather than as a primary immunogen. It is not clear whether the difference in the immune responses to SC602 and SFL124 live oral Shigella vaccines in developing country populations is due to differences in the populations that participated in the clinical trials, to the inherent immunogenicity of the two strains or to disparities in the immunological assays.
Shigella conjugate vaccines
Investigators at the National Institute of Child Health and Human Development (NICHD) in the United States have proposed that in subjects immune to Shigella small amounts of serum IgG transude onto the gut surface, where they can neutralize or otherwise inactivate inocula of wild-type Shigella organisms shortly after ingestion 109, 110 (FIG. 3) . On the basis of this concept, NICHD investigators have developed parenteral conjugate vaccines that consist of O polysaccharides derived from the LPS of relevant Shigella serotypes covalently linked to a carrier protein (Pseudomonas aeruginosa exotoxin A (PsA) or CRM9-mutant diphtheria toxin). Data supporting the concept that serum IgG anti-O-antigen antibodies correlate with (and might mediate) protection come from the seroepidemiological studies of Cohen and colleagues 111, 112, 131 . Baseline serum specimens were obtained from Israeli military conscripts upon deployment to training bases where they were exposed to a high risk of shigellosis 111, 112, 131 . 113, 114 . In a randomized, controlled, double-blind Phase III efficacy trial involving several hundred Israeli soldiers, a single dose of the S. sonnei conjugate vaccine conferred 74% protection against S. sonnei diarrhoea during outbreaks on army bases 114 . The efficacy of the vaccine was related to the level of conjugate-induced IgG anti-O-antigen antibody.
Phase II trials assessed the clinical acceptability and immunogenicity of S. sonnei (conjugated to PsA or CRM9) and S. flexneri 2a (conjugated to PsA) vaccines in Israeli children that were 4-7 and 1-4 years of age 115, 116 . In these paediatric studies, a two-dose immunization schedule was used, with doses spaced 6 weeks apart 115, 116 . The first injection of each vaccine stimulated a significant (9-13-fold) rise in homologous serum IgG anti-O-antigen antibodies 116 . In 1-4-year-olds, the second injection stimulated a booster response in both recipients of S. sonnei (2.9-fold) and S. flexneri 2a (1.6-fold) conjugates; the titres remained elevated 2 years after vaccination 116 . A Phase III randomized efficacy trial of S. sonnei conjugate and S. flexneri 2a conjugate vaccines, with each serving as a control for the other, was recently completed in paediatric subjects in Israel. The results of this trial will determine whether the S. sonnei conjugate vaccine can protect young children. The next generation of Shigella conjugates, based on synthetic oligosaccharides linked to proteins, offers promise for enhanced immunogenicity and diminished production costs 117 .
Strategies to achieve broad-spectrum protection Arguably the greatest impediment to achieving a useful Shigella vaccine is devising a strategy that can confer broad protection against a large number of epidemiologically relevant serotypes. There is widespread agreement that a global Shigella vaccine must protect against 16 serotypes and subserotypes, namely S. dysenteriae 1, S. sonnei and all 14 classical S. flexneri types and subserotypes ( 
. CVD investigators have demonstrated in a guinea pig model that a multivalent vaccine containing serotypes S. flexneri 2a and S. flexneri 3a provides an impressive level of cross-protection against other S. flexneri serotypes that share the common O-antigen epitopes 118 .
As Ipa and VirG proteins are plasmid-encoded virulence attributes that are expressed by all virulent Shigella, irrespective of serotype, it is attractive to propose basing broad protection on stimulating serological and CMI responses to these (and perhaps to other common protein) antigens (FIG. 3) . However, such responses will have to be even stronger than those elicited by wild-type infection (FIG. 3) . This is because NHP challenges and epidemiological data suggest that protection due to wildtype infection does not confer serogroup -heterologous cross-protection, despite eliciting serological responses to Ipa proteins 53 .
The way forward Identification of the correlates of protection is arguably the most crucial catalyst needed to accelerate the development of effective Shigella vaccines. Although attractive candidate vaccines have entered clinical development, the road ahead presents barriers to be overcome. Whether the pentavalent strategy of the CVD can provide broad cross-protection in humans remains an important question. Also, we must document whether Shigella vaccines -live oral or parenteral conjugate -can protect vulnerable immunologically naive paediatric populations in developing countries as well as travellers from developed countries. Once vaccines have been developed that overcome the biological and epidemiological hurdles and result in licensed products, realization of the potential of vaccines as public health tools will require that yet other hurdles be surmounted, including generating political will and devising financial solutions to assure the introduction and programmatic use of vaccines in developing countries. The advent of the Global Alliance for Vaccines and Immunisation (GAVI) and its Fund, Advanced Market Commitments, the International Finance Facility for Immunisation and other innovative tools for financing the purchase of vaccines for the poorest developing countries offer tangible solutions that were unimaginable a decade ago. These innovations offer optimism that the fruits of microbiological and immunological research, such as the development of well tolerated, effective Shigella vaccines, can reach the neediest target populations.
